These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 15006012)

  • 41. Role of budget impact in drug reimbursement decisions.
    Cohen JP; Stolk E; Niezen M
    J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research.
    van Nooten F; Holmstrom S; Green J; Wiklund I; Odeyemi IA; Wilcox TK
    Drug Discov Today; 2012 Jun; 17(11-12):615-22. PubMed ID: 22366662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Working toward a common currency: is standardization of cost-effectiveness analysis possible?
    Luce BR
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S19-22. PubMed ID: 7493194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions].
    Persson U; Ramsberg J
    Lakartidningen; 2007 Oct 17-23; 104(42):3046-50. PubMed ID: 17985712
    [No Abstract]   [Full Text] [Related]  

  • 46. Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors.
    Wang YR; Pauly MV
    Manag Care Interface; 2005 Aug; 18(8):39-45. PubMed ID: 16127891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
    Hoomans T; Severens JL; van der Roer N; Delwel GO
    Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of pharmacoeconomic data in formulary selection.
    Hatoum HT; Freeman RA
    Top Hosp Pharm Manage; 1994 Jan; 13(4):47-53. PubMed ID: 10130683
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Applying decision analysis to pharmacy management and practice decisions.
    Barr JT; Schumacher GE
    Top Hosp Pharm Manage; 1994 Jan; 13(4):60-71. PubMed ID: 10130685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using cost-effectiveness analysis for formulary decision making: from theory into practice.
    Detsky AS
    Pharmacoeconomics; 1994 Oct; 6(4):281-8. PubMed ID: 10147465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Evaluation of reimbursement applications for new drugs].
    Aaserud M; Trommald M; Oxman AD; Innvaer S
    Tidsskr Nor Laegeforen; 2002 Nov; 122(27):2619-23. PubMed ID: 12523192
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Medical problems associated with the national reference pricing system in Hungary].
    Kerpel-Fronius S
    Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.
    Berndt ER; Glennerster R; Kremer MR; Lee J; Levine R; Weizsäcker G; Williams H
    Health Econ; 2007 May; 16(5):491-511. PubMed ID: 17013993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Update and evaluation of Australian guidelines. Government perspective.
    Mitchell A
    Med Care; 1996 Dec; 34(12 Suppl):DS216-25. PubMed ID: 8969329
    [No Abstract]   [Full Text] [Related]  

  • 59. Australian managed entry scheme: a new manageable process for the reimbursement of new medicines?
    Wonder M; Backhouse ME; Sullivan SD
    Value Health; 2012 May; 15(3):586-90. PubMed ID: 22583471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluating the role of bias in pharmacoeconomic studies.
    Joish VN
    Manag Care Interface; 2001 Aug; 14(8):57-60. PubMed ID: 11517839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.